Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients

American Journal of Transplantation

Volumn 13, Issue 4, 2013, Pages 1026-1033

  Baluch, A ^a   Humar, A ^a   Eurich, D ^b   Egli, A ^a   Liacini, A ^c   Hoschler, K ^d   Campbell, P ^a   Berka, N ^c   Urschel, S ^a   Wilson, L ^a   Kumar, D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Immunogenicity; immunosuppression; serology, vaccine

Indexed keywords

ALLOANTIBODY; HLA ANTIBODY; INFLUENZA VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ALLOIMMUNITY; ANTIBODY PRODUCTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; ERYTHEMA; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; SKIN INDURATION; TREATMENT RESPONSE;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; ISOANTIBODIES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875754843     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12149     Document Type: Article

References (26)

1. Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287-291. (Pubitemid 36330248)
2. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: A multicentre cohort study. Lancet Infect Dis 2010; 10: 521-526.
3. Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89: 1028-1033.
4. Ng BJ, Glanville AR, Snell G, et al. The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant 2011; 11: 568-574.
5. Briggs JD, Timbury MC, Paton AM, Bell PR,. Viral infection and renal transplant rejection. Br Med J 1972; 4: 520-522.
6. Danzinger-Isakov L, Kumar D,. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (Suppl 4): S258-S262.
7. Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011; 11: 2020-2030.
8. Manuel O, Humar A, Berutto C, et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant 2011; 30: 679-684.
9. Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011; 11: 1727-1733.
10. World Health Organization (WHO). 2007 [July 8, 2011]; Available from: http://www.who.int/vaccine-research/diseases/influenza/Guidelines-regulatory- preparedness-pandemic-influenza-vaccines.pdf.
11. Ellis JS, Zambon MC,. Molecular analysis of an outbreak of influenza in the United Kingdom. Eur J Epidemiol 1997 Jun; 13: 369-372. (Pubitemid 27306182)
12. Kimball PM, Baker MA, Wagner MB, King A,. Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011; 79: 1131-1137.
13. Reed E, Rao P, Zhang Z, et al. Validation of the Luminex Platform to Detect and Quantify HLA Antibodies: Assessment of Manufacture Variability by 7 CTOT Core Laboratories. American Transplant Congress; Boston, USA 2012.
14. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
15. Bray RA, Gebel HM,. Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant 2009; 14: 392-397.
16. Durando P, Fenoglio D, Boschini A, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008; 15: 253-259. (Pubitemid 352025530)
17. Manuel O, Humar A, Chen MH, et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 2007; 7: 2567-2572. (Pubitemid 47561624)
18. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351: 2286-2294. (Pubitemid 39552744)
19. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F,. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin 2010; 6: 346-354.
20. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine 2009; 27: 7304-7312.
21. Ritter ML, Pirofski L,. Mycophenolate mofetil: Effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transplant Infect Dis 2009; 11: 290-297.
22. Goodwin K, Viboud C, Simonsen L,. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24: 1159-1169. (Pubitemid 43202262)
23. INTANZA, Influenza Vaccine (Split Virion, Inactivated) [package insert]. Lyon, France: Sanofi Pasteur SA; 2010.
24. Schaffer SA, Husain S, Delgado DH, Kavanaugh L, Ross HJ,. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am J Transplant 2011; 11: 2751-2754.
25. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J,. " Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111-1115.
26. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.